Detail akcie Oragenics Rg online

Business Summary: Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Oragenics Inc revenues was not reported. Net loss increased 5% to $7.6M. Higher net loss reflects Interest expense increase from $19K to $778K (expense), General and administrative increase of 8% to $5.1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$47.62 to -$8.72.